Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eylea in neovascular age-related macular degeneration extension study
NCT00964795Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2009
- Primary completion
- Aug 2013
- Countries
- 2
01
Overview
A Phase 3 trial of aflibercept in neovascular age-related macular degeneration (NVAMD), sponsored by Regeneron Pharmaceuticals. Started Dec 2009; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00964795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00964795.